Name | Teneliximab |
---|
Description | Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion[1]. |
---|---|
Related Catalog | |
In Vitro | Teneliximab (Chi220, BMS-224819) 的作用不仅仅是通过清除CD20承载细胞介导的,联合治疗没有显著损害已建立的抗病毒免疫[2]。 |
References |
No Any Chemical & Physical Properties |